Mycophenolate Tablets to Prevent Immune Rejection of Transplants: Studies on Novel Mycophenolate Sodium Enteric Tablets to Prevent Immune rejection of Organ Transplants - Softcover
Synopsis
Immunosuppressive therapy aims to prevent acute rejection and optimise the function of the transplanted organ. Mycophenolate sodium is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic and immunosuppressive properties used to prevent rejection of kidney transplants. It Inhibits inosine monophosphate dehydrogenase (IMPDH) and blocks the generation of guanosine nucleotides in the de novo pathway of DNA synthesis in the T cell. It is administered orally, at a recommended dose of 1.44 g per day. Mycophenolate sodium is available in 180-mg and 360-mg tablets. An enteric-coated formulation of Mycophenolate sodium is being developed and is currently in Phase IV clinical trial. This book provides insights on formulation development and in vitro evaluation aspects of Mycophenolate sodium enteric tablets which include HPLC analytical method development, compatibility studies, formulation development, evaluation of dosage forms, drug release and stability studies.
"synopsis" may belong to another edition of this title.
Search results for Mycophenolate Tablets to Prevent Immune Rejection of...
Seller Image
Mycophenolate Tablets to Prevent Immune Rejection of Transplants
Published by
LAP LAMBERT Academic Publishing Jun 2021, 2021
ISBN 10: 6203926779
ISBN 13: 9786203926774
New
Taschenbuch
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Immunosuppressive therapy aims to prevent acute rejection and optimise the function of the transplanted organ. Mycophenolate sodium is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic and immunosuppressive properties used to prevent rejection of kidney transplants. It Inhibits inosine monophosphate dehydrogenase (IMPDH) and blocks the generation of guanosine nucleotides in the de novo pathway of DNA synthesis in the T cell. It is administered orally, at a recommended dose of 1.44 g per day. Mycophenolate sodium is available in 180-mg and 360-mg tablets. An enteric-coated formulation of Mycophenolate sodium is being developed and is currently in Phase IV clinical trial. This book provides insights on formulation development and in vitro evaluation aspects of Mycophenolate sodium enteric tablets which include HPLC analytical method development, compatibility studies, formulation development, evaluation of dosage forms, drug release and stability studies. 68 pp. Englisch. Seller Inventory # 9786203926774
Seller Image
Mycophenolate Tablets to Prevent Immune Rejection of Transplants
Published by
LAP LAMBERT Academic Publishing, 2021
ISBN 10: 6203926779
ISBN 13: 9786203926774
New
Softcover
Seller: moluna, Greven, Germany
Seller rating 5 out of 5 stars
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Rajesh Kumar PuttaDr. P. Rajesh Kumar, M. Pharm.,Ph.D. in Pharmaceutics from RGUHS, Bengaluru, Karnataka He has about 15 years of teaching and research experience. He Published 42 research papers in journals. Currently Dr. Rajesh is. Seller Inventory # 490542106
Buy New
£ 30.22
£ 41.97 shipping
Ships from Germany to U.S.A.
Ships from Germany to U.S.A.
Quantity: Over 20 available
Seller Image
Mycophenolate Tablets to Prevent Immune Rejection of Transplants
Published by
LAP LAMBERT Academic Publishing Jun 2021, 2021
ISBN 10: 6203926779
ISBN 13: 9786203926774
New
Taschenbuch
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Immunosuppressive therapy aims to prevent acute rejection and optimise the function of the transplanted organ. Mycophenolate sodium is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic and immunosuppressive properties used to prevent rejection of kidney transplants. It Inhibits inosine monophosphate dehydrogenase (IMPDH) and blocks the generation of guanosine nucleotides in the de novo pathway of DNA synthesis in the T cell. It is administered orally, at a recommended dose of 1.44 g per day. Mycophenolate sodium is available in 180-mg and 360-mg tablets. An enteric-coated formulation of Mycophenolate sodium is being developed and is currently in Phase IV clinical trial. This book provides insights on formulation development and in vitro evaluation aspects of Mycophenolate sodium enteric tablets which include HPLC analytical method development, compatibility studies, formulation development, evaluation of dosage forms, drug release and stability studies.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 68 pp. Englisch. Seller Inventory # 9786203926774
Seller Image
Mycophenolate Tablets to Prevent Immune Rejection of Transplants : Studies on Novel Mycophenolate Sodium Enteric Tablets to Prevent Immune rejection of Organ Transplants
Published by
LAP LAMBERT Academic Publishing, 2021
ISBN 10: 6203926779
ISBN 13: 9786203926774
New
Taschenbuch
Seller: AHA-BUCH GmbH, Einbeck, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Immunosuppressive therapy aims to prevent acute rejection and optimise the function of the transplanted organ. Mycophenolate sodium is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic and immunosuppressive properties used to prevent rejection of kidney transplants. It Inhibits inosine monophosphate dehydrogenase (IMPDH) and blocks the generation of guanosine nucleotides in the de novo pathway of DNA synthesis in the T cell. It is administered orally, at a recommended dose of 1.44 g per day. Mycophenolate sodium is available in 180-mg and 360-mg tablets. An enteric-coated formulation of Mycophenolate sodium is being developed and is currently in Phase IV clinical trial. This book provides insights on formulation development and in vitro evaluation aspects of Mycophenolate sodium enteric tablets which include HPLC analytical method development, compatibility studies, formulation development, evaluation of dosage forms, drug release and stability studies. Seller Inventory # 9786203926774
Seller Image
Mycophenolate Tablets to Prevent Immune Rejection of Transplants | Studies on Novel Mycophenolate Sodium Enteric Tablets to Prevent Immune rejection of Organ Transplants
Published by
LAP LAMBERT Academic Publishing, 2021
ISBN 10: 6203926779
ISBN 13: 9786203926774
New
Taschenbuch
Seller: preigu, Osnabrück, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. Mycophenolate Tablets to Prevent Immune Rejection of Transplants | Studies on Novel Mycophenolate Sodium Enteric Tablets to Prevent Immune rejection of Organ Transplants | Putta Rajesh Kumar | Taschenbuch | Englisch | 2021 | LAP LAMBERT Academic Publishing | EAN 9786203926774 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. Seller Inventory # 120373904